Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:SLDB

Solid Biosciences Q1 2024 Earnings Report

Solid Biosciences logo
$7.63 +0.25 (+3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$7.72 +0.09 (+1.11%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Solid Biosciences EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.57
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Solid Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Solid Biosciences Announcement Details

Quarter
Q1 2024
Date
5/15/2024
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
2:30AM ET

Upcoming Earnings

Solid Biosciences' Q2 2026 earnings is estimated for Thursday, May 21, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Solid Biosciences' Q1 2024 Press ReleasePress Release
(8-K)
Solid Biosciences' Q1 2024 Quarterly reportQuarterly report
(10-Q)

Solid Biosciences Earnings Headlines

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)
 |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SLS-Q/pressreleases/1931391/analysts-offer-insights-on-healthcare-companies-solid-biosciences-sldb-sellas-life-sciences-group-sls-and-legend-biotech-legn/
Solid Biosciences (NASDAQ:SLDB) Price Target Lowered to $16.00 at Wedbush
May 14 at 4:35 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30777927
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
May 14 at 1:00 AM  |  Paradigm Press (Ad)
Solid Biosciences (SLDB) to Release Quarterly Earnings on Thursday
May 14 at 1:30 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30776558
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
May 12 at 4:08 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3293411/0/en/solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-updates.html
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Analysts
May 12 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30772718
See More Solid Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email.

About Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector. In addition to SGT‐001, the company is advancing next-generation programs including SGT-003, a CRISPR/Cas9‐based gene editing approach aimed at correcting specific dystrophin gene mutations, and proprietary assays for sensitive detection of dystrophin expression in muscle tissue.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Solid Biosciences leverages partnerships with academic institutions and patient advocacy groups to support clinical development and expand its understanding of DMD biology. Its clinical studies have been conducted at sites across the United States and Europe, reflecting the global nature of DMD research and the need for broad patient enrollment in rare-disease trials.

Under the leadership of Chief Executive Officer Ilan Ganot, Solid Biosciences maintains a network of research and manufacturing collaborations to enhance vector production and assay development. The company’s mission remains to deliver transformative therapies to DMD patients by advancing innovative genetic medicines and building the infrastructure required for efficient clinical translation.

View Solid Biosciences Profile
Earnings Tools